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A B S T R A C T
This meeting report is based on presentations given at the first Drug Safety Africa Meeting in Potchefstroom,
South Africa from November 20–22, 2018 at the North-West University campus. There were 134 attendees
(including 26 speakers and 34 students) from the pharmaceutical industry, academia, regulatory agencies as well
as 6 exhibitors. These meeting proceedings are designed to inform the content that was presented in terms of
Safety Pharmacology (SP) and Toxicology methods and models that are used by the pharmaceutical industry to
characterize the safety profile of novel small chemical or biological molecules. The first part of this report
includes an overview of the core battery studies defined by cardiovascular, central nervous system (CNS) and
respiratory studies. Approaches to evaluating drug effects on the renal and gastrointestinal systems and murine
phenotyping were also discussed. Subsequently, toxicological approaches were presented including standard
strategies and options for early identification and characterization of risks associated with a novel therapeutic,
the types of toxicology studies conducted and relevance to risk assessment supporting first-in-human (FIH)
clinical trials and target organ toxicity. Biopharmaceutical development and principles of immunotoxicology
were discussed as well as emerging technologies. An additional poster session was held that included 18 posters
on advanced studies and topics by South African researchers, postgraduate students and postdoctoral fellows.
1. Introduction: drug safety in Africa
New drugs are beginning to make inroads against some of the most
important and debilitating diseases threatening mankind. The need is
still great in western countries, in which ageing populations face the
onset of diseases of the central nervous system (e.g., Alzheimer's dis-
ease, Parkinson's disease and psychiatric diseases), the cardiovascular
system (e.g., arterial disease with associated stroke and myocardial in-
farction), Diabetes (and associated long-term complications including
cardiovascular and peripheral arterial disease and stroke) and cancer.
Africa is further challenged with the still high incidence of HIV and
related autoimmune diseases, as well as carrier-mediated infectious
diseases such as malaria. Furthermore, the high incidence of auto-
immune disease has led to a reemergence of secondary diseases thought
to be eradicated in most Western cultures, with tuberculosis being an
important example. Thus, the medical need in Southern Africa goes
beyond those diseases that are the primary focus of major pharma-
ceutical development in Europe, North America and Japan, and the
financial incentive for large pharma to become active to address these
important needs is lacking.
The hallmark of any new, successful medicine is the clinical proof of
efficacy and proof of its safety with clinical use. Thus, drug safety and
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tolerability are a prerequisite for dealing with the current medical
needs of the world, including those of Africa. Most of this work has not
been conducted in Africa but times are changing and new infrastructure
is being put into place to fill this void (Guth & Grobler, 2018). It is time
to bring drug safety into Africa for the benefit of the population. For the
first time, an international conference was held to bring together
African experts with others across the world to discuss current ap-
proaches and challenges to drug safety testing.
Drug Safety Africa 2018 was a first for Africa. The conference pre-
sented state-of-the-art lectures from academic and industry scientists
involved in drug safety testing. African scientists originating from
Ghana, Cameroon, Nigeria, Lesotho, Mauritius and South Africa met
with experts from Europe (Germany, Switzerland, France, and the
Netherlands), UK, USA and South America over three days in a con-
centrated, interactive lecture series. Four main areas of drug safety
were addressed at this conference: safety pharmacology, toxicology,
clinical drug safety and precision medicine. Each day included plenary
lectures by international experts describing newly developed methods
and approaches to enhance the prediction of drug safety with their
ultimate use in a diverse patient population. Of particular interest and a
dedicated focus point for the plenary lectures, was the degree of
translation between both in vitro and in vivo preclinical studies to first-
in-man clinical trials and to further, larger clinical trials.
The conference thus provided a forum for South African scientists,
postgraduate students and postdoctoral fellows to learn about new
developments in drug safety testing. The conference also provided a
forum for identifying new partnerships and collaborations devoted to
finding new, safe drugs to address unmet medical need in Africa and
world-wide. In addition, the meeting showcased the newly established
drug safety testing infrastructure within Southern Africa.
2. Safety pharmacology in drug development
The central nervous, cardiovascular and respiratory systems are
designated as vital-for-life and the tests that address possible drug-in-
duced effects on these physiological systems have been designated the
‘Safety Pharmacology Core Battery’ of studies (Pugsley, Authier, &
Curtis, 2008). These are outlined in the ICHS7A and ICH S7B regulatory
guidance documents that were first published by the US FDA in 2001
(Anon, 2001) and 2005 (Anon, 2005a, Anon, 2005b), respectively.
2.1. An overview of safety pharmacology and the safety pharmacology
society (Michael K. Pugsley, safety pharmacology society, Fairfield, CT,
USA)
Dr. Pugsley opened the conference by providing an overview of the
discipline of SP and the mandate of the Safety Pharmacology Society
(SPS). Safety Pharmacology studies are conducted to predict whether
novel drugs (new chemical entities (NCE)) are safe for human use. Non-
clinical safety pharmacology studies aim to detect and characterize
potentially undesirable pharmacodynamic activities using an array of in
silico, in vitro and in vivo animal models (Pugsley et al., 2008; Pugsley
et al., 2018). Methodological innovation and advancement of drug
safety science is driven through the hard work of members of SPS. The
society also focuses on important partnerships with both regulatory
authorities and technology providers and facilitates interaction with
organizations of common interest such as primary pharmacology and
toxicology. Education is a priority of the SPS and this is driven by
content at both regional e.g., US Northeast and European meetings and
the Annual SPS general meeting (https://safetypharmacology.org/
meetings_sps.asp). The society also generates added educational con-
tent through the conduct of monthly, highly topical webinars and the
publication of manuscripts derived from studies presented at the annual
SPS meeting. This publication occurs as a focused issue in the Journal of
Pharmacological & Toxicological Methods. Ultimately, however, all edu-
cational material is made available to inform the general drug safety
and regulatory community regarding progress made by members (or
groups) within the society (Pugsley et al., 2018). To advance the dis-
cipline, the SPS sets achievable goals, determining actions to success-
fully achieve those goals, and mobilizing society resources to support
those actions. As the discipline is evolving rapidly, the SPS provides
coverage of novel methods and models for use in drug safety testing and
this is certain to expand to provide better guidance for more types of
test systems (Pugsley, Harter, et al., 2018). Dr. Pugsley's lecture pro-
vided key information regarding the establishment of the discipline of
Safety Pharmacology which remains distinct from related medical dis-
ciplines including pharmacology, biochemistry, physiology and tox-
icology; however, conveyed its reliance on these fundamental fields to
evaluate the safety profile of an NCE.
2.2. Drug-induced effects on the respiratory system (Michael K. Pugsley,
safety pharmacology society, Fairfield, CT, USA)
Dr. Pugsley outlined methods used to investigate drug-induced ef-
fects on the respiratory system during the evaluation of a NCE or bio-
logical molecule (i.e., a protein, peptide or monoclonal antibody). All
use standard endpoints such as respiratory rate and pulmonary tidal
volume (Murphy, 2014). While anesthetized animals may be used to
conduct these studies, the use of anesthetized animal models is strongly
discouraged in SP studies since cardio-pulmonary reflexes are damped
by anesthetics (Anon, 2001). Alternatively, conscious animals can be
studied using whole body plethysmography or through the placement
of a pressure-sensitive catheter (attached to a radiotelemetry trans-
mitter) beneath the pleural surface (Murphy, Renninger, & Coatney,
2001; Murphy, Renninger, & Gossett, 1998). A similar method has been
developed for use in the conscious non-human primate (NHP) which
may be useful in the evaluation of biological molecules that may re-
quire the NHP as a test species (Murphy et al., 2001). Numerous end-
points are accessible, including ventilatory flow rates (i.e., flow volume
and time), arterial blood gases, blood pH, hemoglobin‑oxygen satura-
tion and pulmonary receptor function. Similarly, these methods can
also measure lung mechanics including changes in pulmonary pressure,
pulmonary resistance and lung dynamic compliance (Murphy, 2014).
Recently, Murphy (2016) showed that a quantitative measurement of
apnea or hyperventilation can also be made in telemetered animals that
ensure accurate monitoring at both low and high respiration rates. The
ability of a drug to cause ventilatory instability should also be con-
sidered because chronic disruption can result in a multitude of adverse
events due to intermittent hypoxia. Ventilatory instability is easily
identified by the presence of prolonged end-expiratory pauses or apneic
periods. Thus, safety pharmacologists continue to refine respiratory
methods for use in the preclinical detection of potential NCE and bio-
logical molecule adverse event liability. However, a re-evaluation of
standard respiratory models and novel study endpoints is long overdue
by the safety pharmacology community.
2.3. Drug-induced effects on the cardiovascular system (focus on telemetry
based CV models in non-rodents) (Michael Markert, Boehringer Ingelheim
Pharma GmbH + Co KG, Biberach, Germany)
Drug-induced effects on the cardiovascular (CV) system are of par-
ticular importance and can be investigated in conscious, unrestrained
animals using telemetry-based technology (Markert et al., 2004;
Klumpp et al., 2006). This methodology allows for continuous mon-
itoring of CV parameters but produces very large data sets. Thus, a
cloud-based transmission and real-time analysis of the recorded phy-
siological signal system was developed (Markert et al., 2017). This
system allowed for an assessment of physiological signals despite a
substantial geographic separation between the instrumented animals
and the evaluating home laboratory. Mr. Markert described an ap-
proach for handling and evaluating such data sets. Animals (dogs, mini-
pigs or cynomolgus monkey) were instrumented with a newly designed
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full-implanted telemetry based device allowing for measurement of
aortic blood pressure, left ventricular pressure, ECG and body tem-
perature. After recovery, animals were randomly assigned to cross-over
design studies testing drugs at three different oral doses together with
the vehicle used. The data were acquired on a beat-to-beat basis, con-
tinuously throughout the observation period. To allow for data visua-
lization and statistical analysis, the data was binned as 10min median
values and stored in an Oracle database. Spotfire® was used for visua-
lization of the data and all statistical analyses were performed using
SAS®. Excellent signal quality was obtained and stable hemodynamic
parameters were measured in all species. An example of this high signal
quality and stable parameters with low variability can be found for the
minipig in the report from Markert, et al. (Markert et al., 2009). Be-
tween 120,000 (dogs) and 400,000 (cynomolgus) heart beats are typi-
cally analyzed per study. Access to the stored data was fast using the
SAS® and Spotfire® systems and resulted in both a graphic illustration
and statistical analysis within a short time after finishing the data ac-
quisition. NOTOCORD-sense® was used to perform the cloud-based data
collection and transmission and real-time data analysis. Large data sets
generated in CV studies present a challenge for data reduction and
evaluation. The approach described offers convenient data handling
and a flexible graphic illustration of the summarized data to enhance
and speed study evaluation. The implants used were well tolerated and
the animals recovered rapidly from the instrumentation procedure.
Excellent signal quality was obtained and stable hemodynamic and
electrophysiological parameters could be measured. We successfully
showed that a remote cloud-based data acquisition for real-time, beat-
to-beat (cardiovascular) data collection by telemetry is feasible.
Drug-induced effects on the cardiovascular (CV) system are of par-
ticular importance and can be investigated in conscious, unrestrained
animals using telemetry-based technology (Markert et al., 2004;
Klumpp et al., 2006). This methodology allows for continuous mon-
itoring of CV parameters but produces very large data sets. Thus, a
cloud-based transmission and real-time analysis of the recorded phy-
siological signal system was developed (Markert et al., 2017). This
system allowed for an assessment of physiological signals despite a
substantial geographic separation between the instrumented animals
and the evaluating home laboratory. Mr. Markert described an ap-
proach for handling and evaluating such data sets. Animals (dogs, mini-
pigs or cynomolgus monkey) were instrumented with a newly designed
full-implanted telemetry based device allowing for measurement of
aortic blood pressure, left ventricular pressure, ECG and body tem-
perature. After recovery, animals were randomly assigned to cross-over
design studies testing drugs at three different oral doses together with
the vehicle used. The data were acquired on a beat-to-beat basis, con-
tinuously throughout the observation period. To allow for data visua-
lization and statistical analysis, the data was binned as 10min median
values and stored in an Oracle database. Spotfire® was used for visua-
lization of the data and all statistical analyses were performed using
SAS®. Excellent signal quality was obtained and stable hemodynamic
parameters were measured in all species. An example of this high signal
quality and stable parameters with low variability can be found for the
minipig in the report from Markert, et al. (Markert et al., 2009). Be-
tween 120,000 (dogs) and 400,000 (cynomolgus) heart beats are typi-
cally analyzed per study. Access to the stored data was fast using the
SAS® and Spotfire® systems and resulted in both a graphic illustration
and statistical analysis within a short time after finishing the data ac-
quisition. NOTOCORD-sense® was used to perform the cloud-based data
collection and transmission and real-time data analysis. Large data sets
generated in CV studies present a challenge for data reduction and
evaluation. The approach described offers convenient data handling
and a flexible graphic illustration of the summarized data to enhance
and speed study evaluation. The implants used were well tolerated and
the animals recovered rapidly from the instrumentation procedure.
Excellent signal quality was obtained and stable hemodynamic and
electrophysiological parameters could be measured. We successfully
showed that a remote cloud-based data acquisition for real-time, beat-
to-beat (cardiovascular) data collection by telemetry is feasible.
2.4. The minipig as test species for safety pharmacology studies (Andrea
Greiter-Wilke, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd,
Basel, Switzerland)
Dr. Greiter-Wilke discussed the use of the minipig in SP studies
designed to detect potential cardiovascular effects of new drugs. The
Göttingen minipig was originally bred at the University of Göttingen by
crossing breeding the Minnesota minipig with the Vietnamese potbelly
pig and the German landrace pig in order to obtain a relatively small
and gentle breed. Its use as a non-rodent species in both toxicity and
safety pharmacology studies is gaining acceptance within the pharma-
ceutical industry and by different regulatory agencies (Forster, Bode,
Ellegaard, & van der Laan, 2010). Minipigs reach sexual maturity at 4 to
5months of age and weigh approximately 10 kg at this time (McAnulty,
Dayan, Ganderup, & Hastings, 2012). If kept long-term for use in tele-
metry studies, their weight can remain below 35 kg with strict food
control. Minipigs can easily be trained and group housed. The common
routes of administration can be performed similarly as in the dog and
the monkey; however, more manpower may be needed for restraint.
The use of telemetry-based data acquisition and the needed in-
strumentation is comparable to other species, but the ECG leads of the
implant should be of sufficient length to account for the growth of the
animal. The resting heart rate of minipigs is comparable to dogs at
60–80 beats/min (Kuwahara et al., 2004; Markert et al., 2009) and
therefore lower than the monkey. When being fed, the heart rate of the
minipig will increase for several hours, which needs to be taken into
account in the study design (Stubhan et al., 2008; Yuan et al., 2014). In
minipigs the QT interval of the ECG is longer compared to other species
and it is also advised to correct QT for heart rate changes with an in-
dividual correction formula (Holzgrefe et al., 2014). Moxifloxacin,
which is commonly used as a positive control drug for prolongation of
the QT interval, has been shown to prolong the QT interval in the
minipig (Markert et al., 2009) even to a greater extent than in other
species at comparable doses and plasma drug levels (Holzgrefe et al.,
2014). Minipigs can be rather sensitive to drug-induced body tem-
perature decreases, which will lead to increases in the QT interval and
this needs to be interpreted accordingly. The characterization of phar-
macokinetic drug profiles in the Göttingen minipig, when reference
human drugs are used, revealed comparable PK data to dog or monkey
(Lignet et al., 2016). Major metabolic pathways (Phases I and II) are
present in the minipig and are consistent with human and other non-
clinical toxicology species, with the exception of an increased amide
hydrolysis which might lead to reduced human metabolic coverage
(Jones et al., 2016). Gastric emptying can be prolonged, especially
when animals are kept on straw (Suenderhauf et al., 2014). The use of
minipigs in CNS and respiratory studies is described in the literature
(Willens, Cox, Braue, Myers, & Wegner, 2014; Zhong et al., 2017);
however, these study types have not become as routine as cardiovas-
cular assessments. Thus, the minipig is well suited as an alternative
species to the dog and the monkey for drug safety testing, raises less
ethical concerns and is without the potential issue of limited animal
supply.
2.5. Drug-induced effects on the gastrointestinal and renal systems (Brian
D. Guth, Boehringer Ingelheim Pharma GmbH + Co KG, Biberach,
Germany)
In designing and conducting SP studies, most attention is paid to the
core battery studies that are intended to detect drug-induced effects
that are possibly life threatening even with just a single administration.
Nevertheless, other effects on physiological function can be highly re-
levant to the overall success of a new drug and effects on both gastro-
intestinal and renal function can either lead to drug failure in clinical
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trials or to restricted use based on poor tolerability. Thus, there is a
strong rationale to examine drug candidates for such effects early
during preclinical development. Animal models for this type of testing
have been used successfully for many years (Pairet et al., 1997) and
have been shown to be predictive for effects seen with their clinical use
(Pestel, Martin, Maier, & Guth, 2006). Thus, there are reliable tools
available to make these assessments. The presentation of Dr. Guth fo-
cused on two such rat models, one examining gastrointestinal effects
and the other testing for possible drug-induced effects on renal and
metabolic function.
The first model entails the determination of the rate of gastric
emptying and the extent of intestinal transit in the conscious rat. This
has been used as a screening model in multiple drug discovery projects
and has been used as an optimization test in some projects that have
been associated with gastrointestinal effects. It is a simple test in which
fasted rats are given a test meal of known volume (barium sulfate or
charcoal are typically used) at a predetermined time following the
administration of a test article. The timing of the test meal is usually
chosen to correspond to the expected maximal drug concentration.
Thirty minutes following the administration of the test meal the animals
are euthanized and the extent of emptying of the stomach is measured
as well as the distance that the test meal has travelled into the upper
intestine. Minor modifications of the study protocol make it also sui-
table for use in mice.
Effects of new drugs on renal function can be assessed through urine
analysis and the measurement of serum- based parameters. The eva-
luation includes an assessment of the excretory function of the kidney,
including electrolytes and metabolites. Additionally, markers of po-
tential drug-induced acute renal injury are measured in urine. The
study entails keeping the animals in metabolic cages for the collection
of urine into temperature-controlled collection vessels. During pre-
determined time intervals, urine is collected and analyzed for urinary
volume, electrolyte concentrations, selected metabolites and markers of
renal epithelial stress. At the end of the protocol, blood is drawn and a
variety of parameters are measured in serum to detect possible meta-
bolic effects as well as to measure hepatic enzyme levels as an indica-
tion of acute hepatic stress or possible toxicity.
3. Toxicology in drug development
Nonclinical toxicology has historically been a leading contributor to
attrition of candidate drug compounds (Waring, Arrowsmith, Leach,
et al., 2015). However, there is considerable benefit to patients and
drug discovery companies in identifying and eliminating risks early in
pre-clinical studies rather than in clinical efficacy trials. The toxicology
session was introduced by James Smith (Boehringer-Ingelheim, Ridge-
field, CT) with a review of the strengths and weaknesses in translational
risk characterization by standard toxicity study screening (Butler,
Guzzie-Peck, Hartke, et al., 2017; Valentin, Guillon, Jenkinson, et al.,
2018) with a particular focus on toxicities commonly observed in spe-
cific organ systems.
3.1. Safety assessment from new therapeutic concept to candidate selection
(James Smith, Boehringer-Ingelheim, Ridgefield, CT)
In the first presentation of the toxicology session, James Smith
outlined standard strategies and customized options for early identifi-
cation and characterization of risks associated with a novel therapeutic.
For both small and large molecules, these activities include in silico, in
vitro and in vivo experimental approaches and are most efficiently un-
dertaken in parallel to confirmation of efficacy that ensures swift and
smooth progression to a candidate molecule. The use of a comprehen-
sive, literature-based assessment of risk (hazard and exposure) asso-
ciated with a therapeutic concept against a specific target and the scope
and timing of such an assessment was presented. Such an assessment
considers the strength of evidence for the risk, its severity,
monitorability and the ability to investigate the risk in preclinical
toxicological studies that is translatable to patients in a specific ther-
apeutic indication and duration of treatment (Brennan, 2017; Butler
et al., 2017). In this presentation, emphasis was placed on the benefit of
such an assessment before the identification of a lead molecule for any
drug discovery program and the accessibility of predominantly publicly
available sources of information needed for such an evaluation.
A summary of standard safety screening methods mandated by ICH
guidelines for new chemicals (ICH.org; Anon, 2007) was laid out and
included: genotoxic screening (in silico, bacterial (Ames), in vitro
mammalian cell and in vivo (micronucleus) assays), cytotoxicity,
phospholipidosis and safety pharmacology studies (see above). In ad-
dition, for small molecules there is considerable evidence for the as-
sociation of the physiochemical properties, presence of specific struc-
tures, target binding promiscuity and efficacious dose with preclinical
and clinical toxicities (Bowes, Brown, Hamon, et al., 2012; Greene,
Aleo, Louise-May, et al., 2010; Stepan, Walker, Bauman, et al., 2011;
Sutherland, Raymond, Stevens, et al., 2012; Brennan & Kiessling,
2017). The optimum timing and scope of standard and custom prop-
erty-based safety screens for candidate compounds was discussed as
well as the technical feasibility, due to the requirement for relatively
small amount of compounds, and the significant reduction in the use of
animals. Despite these benefits, established screens do not predict off
target toxicities or those that are influenced by metabolism or bioa-
vailability. More predictive, emerging safety screening approaches for
small molecules using advanced computational approaches, custom in
vitro systems or novel in vivo analyses were briefly introduced (Lamore,
Ahlberg, Boyer, et al., 2017; Liu, Patlewicz, Williams, et al., 2017;
Passini, Britton, Lu, et al., 2017; Peters, Landry, Pin, et al., 2018). These
tools hold great promise for smaller drug discovery organizations due to
high predictivity with minimal investment. The standard safety
screening strategy for large molecule biological therapeutics includes
evaluations of immunogenicity and tissue cross-reactivity, cytokine
release, complement and antibody mediated cytotoxicity (Brennan,
2017). These were introduced briefly but covered in more detail in the
Biologics Development and Immunotoxicology presentation (see
below). Attention was given to novel in silico and custom in vitro and in
vivo assays for de-risking therapeutic candidates that are being devel-
oped to support this highly dynamic and promising class of therapeutics
(Brennan, 2017). In summary, significant savings in time and resources
as well as improved prediction of patient safety is achieved by applying
selected safety assessments in the drug discovery and development
process well before identification of a lead molecule.
3.2. General toxicology programs to support first in human trials for small
molecules and toxicology beyond first in human trials (Danuta Herzyk,
Merck Sharp & Dohme Corp., a subsidiary of Merck & co., Inc., Kenilworth,
NJ, USA)
Dr. Herzyk initially discussed preclinical drug development with an
emphasis on toxicology studies, their objectives, types and relevance to
risk assessment supporting first-in-human (FIH) clinical trials with new
drug candidates. In a second presentation (below), she described the
role of toxicology studies in the progress to later phases of clinical
evaluation that ultimately lead to the approval and marketing author-
ization for a new drug by regulatory agencies.
The development of a new drug is a very long and complex process.
A multitude of activities must be completed before a new medicinal
entity is approved for human use and can be applied to the patient.
Many different preclinical studies focused on safety of a new drug
candidate are required to be conducted prior to progression to clinical
trials (Kramer, Sagartz, & Morris, 2007). In addition to early screening
of drug candidates using in vitro and in vivo pharmacology test systems,
comprehensive and highly regulated toxicology studies in animals are
conducted to enable identification of potential toxicity on one hand and
prediction of safe exposure in humans on the other. Toxicology
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programs are planned according to international regulatory guidelines,
primarily implemented by ICH (Anon, 2007) to promote uniformity in
technical requirements for registration of pharmaceuticals for human
use, and to ensure that safe, effective, and high-quality medicines are
developed and registered in the most efficient and cost-effective
manner.
Preclinical toxicology studies are conducted based on some general
assumptions, including two key premises: 1) that animal models gen-
erally will predict human safety, and 2) the use of high doses in animal
studies will maximize model sensitivity to detect toxic effects. The
objectives of toxicology studies are to identify the target organ of
toxicity, to examine potential gender differences in response to a drug
candidate and to understand if observed effects are expected based on
pharmacology and mechanism of action (on-target) or unexpected (off-
target). When toxicity is observed in animals, it needs to be char-
acterized in relationship to the systemic exposure to a drug candidate,
mainly to establish if there is a linear dose-response. The next step is to
evaluate if the observed toxicity is reversible or progressive, and if it
can be monitored clinically. Toxicology studies are categorized as two
types, pivotal safety studies and exploratory studies. Safety studies are
highly regulated by laws and need to be compliant with Good
Laboratory Practice (GLP) rules to be acceptable by regulatory agencies
that review preclinical data prior to permitting a safe conduct of clinical
trials and registration of new drugs. Exploratory (non-GLP) studies in-
volve investigative work in early screening phases of drug candidates
and/or follow-up studies to characterize the mechanism of toxicity
found in GLP studies.
The quality of toxicology studies is highly dependent on the study
design taking in to account some important considerations. These
considerations include animal species selection, route of administra-
tion, frequency and duration of the drug candidate administration to
animals, and study parameters to be evaluated. Species selection is
based on pharmacokinetic and metabolic profile of a compound, its
pharmacologic activity or other scientific basis. For chemical drugs two
species, one rodent (rat or mouse) and one non-rodent (typically dog or
monkey), are required. Route and frequency of animal dosing needs to
be consistent with route of administration utilized in the clinic.
Chemical drugs are routinely given to study animals by oral (gavage)
administration on a daily basis. However, intravenous, subcutaneous,
intramuscular, inhalation, or dermal administration routes are used
when needed. Duration of toxicology studies ought to cover or exceed
the number of days used for dosing in the clinic. Standard endpoints of
a toxicology study include a battery of antemortem endpoints, such as
clinical observations and body weight, hematology, serum chemistry,
urine analysis, and ophthalmology examination, followed by post-
mortem histopathology examination of all major organs and tissues. In
addition, concentration of a drug in blood plasma is evaluated over the
course of the study. Interpretation of results from a toxicology study
involves the determination of adverse and non-adverse effect levels. A
no-observed-adverse-effect-level (NOAEL) is a dose (or level of ex-
posure) determined by empirical study at which adverse effects (i.e.,
harmful anatomical, biochemical, or functional changes) were not in-
duced by test article administration in that study. A NOAEL is typically
used as push-off point for selection of a starting dose and dose escala-
tion scheme in FIH studies. Clinical doses of novel drug are limited to
exposure that does not exceed the NOAEL in animal toxicology studies.
This rule, however, may not apply to anticancer drugs to be given to
patients with late-stage cancer disease where potential benefit versus
risk from a drug candidate is an important factor. To minimize exposure
to low doses that are unlikely to exhibit expected pharmacological ac-
tivity in cancer patients, the starting dose may represent a severely
toxic dose in 10% (STD) in rodents or 1/6th of highest non-severely
toxic dose (HNSTD) in non-rodents, whichever is lower (Anon, 2010).
In addition to the safety margin determined in toxicology studies based
on the systemic exposure observed in animals versus predicted exposure
in humans, important deliberations in risk assessment include the
nature of the dose-limiting adverse events (e.g., findings in liver vs.
brain), therapeutic indication being sought (e.g., more tolerance for life
threatening cancer), intended patient population (e.g., no reproductive
concerns for post-menopausal women), potential for reversibility of the
observed toxicity, and the ability to monitor the toxicity in the clinic
using biomarkers. Efforts should be made to understand the mechanism
of the observed toxicity. The goal of risk assessment is to establish if the
uncovered adverse effects may be relevant to human health or represent
animal-specific findings.
After a new drug candidate has entered the clinic, toxicology eva-
luation of the drug candidate in animal studies continues in parallel
with the clinical studies during the drug development process. A proof
of therapeutic concept between phase 1 and phase 2 clinical trials, leads
to further efficacy studies in a large population of patients in phase 3
clinical trials. Animal studies supporting these clinical trials include
chronic toxicology, reproductive and developmental toxicity (DART),
and evaluation of carcinogenicity potential. The goal of chronic toxicity
studies is to find out if potential and/or identified toxicity profiles will
change upon prolonged administration of the drug. To support clinical
trials, where patient populations include women of child-bearing po-
tential, DART studies in rats and rabbits are required to evaluate po-
tential pregnancy risk and fetal toxicity upon exposure to the drug.
When the treatment of a disease requires a duration of 6months or
longer, the new drug is evaluated for carcinogenicity risk. For chemical
drugs, typical animal carcinogenicity studies are conducted in rodents
for life time, i.e., 2-year duration in rats and mice. The 2-year mouse
study may be substituted by a 6-month duration in Tg-rasH2 transgenic
mice, which are genetically altered as a tumor sensitive strain. Selection
of doses for these studies as well as predictive interpretation of results
and relevance to human risk are the key components of drug safety
assessment as described above. Also, it is vital to keep in mind that the
potential benefit is just as important as the potential risk associated
with a novel therapeutic.
3.3. A pathologist's perspective on target organ toxicity (ken Frazier,
GlaxoSmithKline, King of Prussia, PA, USA)
Dr. Ken Frazier presented a lecture on target organ toxicity and the
critical role that the pathologist assumes in preclinical toxicology stu-
dies. The pathologist helps develop protocols regarding which tissues to
evaluate, assigns and evaluates clinical pathology parameters, de-
termines appropriate recovery phases if necessary, and supervises ne-
cropsy. Most importantly the pathologist identifies lesions, interprets
treatment-related macroscopic and microscopic findings, and de-
termines cause of death by assessing target organ toxicity. Multiple
examples of important and common lesions noted in animal studies
were presented, with their clinical implications, in liver, kidney, heart,
bone and the blood (Frazier et al., 2012). Common spontaneous back-
ground changes lacking clinical relevance were also discussed, such as
chronic progressive nephropathy, rodent cardiomyopathy and amyloi-
dosis. While liver, kidney and heart are the most common toxicologic
target organs for candidate drugs, it was stressed that any organ may be
affected by drug treatment and a complete list of tissues are examined
macroscopically and microscopically in GLP animal studies to support
first-in-human and later clinical trials (Frazier & Seely, 2018). Pre-
clinical drug-related findings do not necessarily prohibit the initiation
of clinical trials, but are instead utilized to set starting doses in the
clinic and to provide important information for clinicians for mon-
itoring patients. Clinical margins are extremely important as is the
nature of the finding, so the dose and exposure at which changes occur
are equally important in gauging the potential toxicity of a candidate
drug or compound. The role of the pathologist in tumor diagnosis in
carcinogenicity studies and clinical relevance of findings were also
discussed.
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3.4. A pathologist's perspective on adverse vs non-adverse (ken Frazier,
GlaxoSmithKline, King of Prussia, PA, USA)
In Dr. Frazier's second lecture, he discussed the importance of as-
sessing adversity in preclinical toxicity studies and how adversity calls
are determined. The “no observed adverse effect level” (NOAEL), as
discussed in earlier lectures, is expected on reports describing good
laboratory practice (GLP) preclinical toxicity studies by the Food and
Drug Administration, European Medicines Agency, and all other gov-
erning bodies, but adversity can be difficult to apply in practice to many
drug-related effects (Kerlin et al., 2016). Adversity calls in a preclinical
report can highlight potential safety issues that may need to be ad-
dressed in the clinical program by clinical safety personnel and these
adversity calls can impact clinical starting doses and clinical dosing
limitations. There are many nuances and challenges in determining and
interpreting the NOAEL with consistency. A summary definition for
NOAEL and guidelines for its components have been agreed upon by the
toxicology community to facilitate consistency and compatibility across
institutions and among individual pathologists (Kerlin et al., 2016). The
NOAEL as described above (see section 3.2) is a key component of risk
assessment that needs to be established for each drug candidate. To
evaluate the potential for risk in humans, one or more multi-dose an-
imal studies are used to establish the highest level that does not produce
harmful (i.e., adverse) effects. The benchmark dose (BMD), which em-
ploys data modeling to examine the dose response, is used in some
settings as an alternative approach to the NOAEL. Study NOAELs are
established at the level of the overall study report, but each finding in
sub-reports (pathology contribution or clinical pathology contribution,
etc.) can be classified as adverse or not, at a particular dose level. A
finding may be non-adverse at a low dose, but at the high dose may be
of sufficient severity to be considered adverse. Test article-related ef-
fects should be described on their own merits within a study, and not on
whether they may progress with increased dose or longer duration
treatment. Organ effects in a study which are not related to test article
are not evidence for adversity. Adversity does not depend on reversi-
bility and thus whether a drug effect recovers from injury is considered
separately and is not an aspect of the adversity call. In preclinical
summary documents, NOAELs from multiple studies are considered
together to define the most important adverse responses in the most
sensitive species. Some effects that can be modulated by drug treatment
represent exacerbations of incidental background changes that are ir-
relevant and/or have no known human counterparts. When combined
with other information on mechanism, species sensitivity, reversibility
and progression, kinetics and metabolism, data on important adverse
effects in preclinical species can best inform human risk assessment
(Palazzi et al., 2016). A case example was presented involving hyaline
droplets in the kidney to allow congress participants a chance to
practice in adversity assignment of a specific target organ toxicity.
3.5. Biologics development and immunotoxicology (Danuta Herzyk, Merck
Sharp & Dohme Corp., a subsidiary of Merck & co., Inc., Kenilworth, NJ,
USA)
This lecture by Dr. Herzyk was focused on biopharmaceuticals.
Biopharmaceuticals (also called ‘biologics’) are protein-based human-
specific large molecules that differ in many respects from chemical
drugs and their development requires many considerations that are
unique to this group of medicines. Biopharmaceuticals are made in
living cells from plants, yeast, bacteria, insects or mammalian organs
(e.g., Chinese hamster ovary) via DNA recombinant technology. They
are human protein analogs of large size (molecular weight, MW, of
5000 Da – 150,000 Da) and complexity with a highly ordered structure
(primary, secondary and tertiary) as well as being markedly hetero-
geneous in nature. Because of their large size, biologics (in contrast to
chemical drugs with MW of 200–500 Da) do not enter intracellular
organelles, thus do not interact with genetic material, and do not
interact with ion channels that play a crucial role in cardiac electro-
physiology. Because complex protein engineering is applied in con-
structing novel biologics, the production process of a biologic drug is
difficult to duplicate by others or create a copy of the same molecule
using different cell lines, expression systems, etc. In the world of bio-
logics, “the process is the product”. Highly specialized analytical
methods need to be developed to measure and control the stability and
other physicochemical properties of biologics. In addition, their de-
tection in blood for pharmacokinetic evaluation often requires unique,
molecule-specific techniques, e.g., immunoassays or cell-based assays.
As protein-based molecules, biopharmaceuticals are sensitive to
proteolytic enzymes present in the digestive system, therefore, they
cannot be administered orally and need to be injected, typically in-
travenously or subcutaneously. As analogs to human native proteins,
after administration biopharmaceuticals are catabolized and excreted
(mainly via kidney) like other physiologic proteins. Also, biopharma-
ceuticals typically have longer half-live in the blood circulation (i.e.,
days to weeks), which allows for less frequent administration compared
to chemical drugs. Most importantly, biologic drugs bind to desired
therapeutic targets, i.e., soluble or cell surface receptors, with high
specificity, therefore do not exhibit off-target activity or unexpected
toxicity and have very good safety profiles. There are multiple types
and classes of biopharmaceuticals, which include such constructs as
monoclonal antibodies and their derivatives, e.g., fragments or fusion
proteins; recombinant proteins, e.g., physiologically deficient hor-
mones, enzymes or cytokines; multi-specific antibodies; and nano-
bodies. Other types of complex biopharmaceuticals include vaccines
and viral vectors as well as emerging cell therapies and gene therapies.
The type of biopharmaceutical candidate often determines the design
and approaches to its safety testing and toxicology studies. Particularly,
in-depth understanding of the biology of a modulated target by a novel
biopharmaceutical plays a crucial role in the selection of appropriate
and relevant animal species for the evaluation of its safety. Also, bio-
logic drugs, being large proteins with some “unnatural” modifications,
have a potential to be recognized by a treated host's immune system
and result in production of anti-drug antibodies. Such anti-drug anti-
body responses to the treatment, often referred to as immunogenicity,
needs to be considered in toxicology studies in animals. During the
lecture, Dr. Herzyk provided reference to the key regulatory guidance,
ICH S6(R1) (Anon, 2011) and its salient points that give directions to
animal species selection as well as immunogenicity evaluation in pre-
clinical studies with biologic molecules (Ponce et al., 2009). Many
unique features of biologic drug candidates and recommendations for
their safety testing are also addressed in published literature
(Cavagnaro, 2008; Plitnick & Herzyk, 2013). Those aspects were dis-
cussed using “compare and contrast” summary of approaches and stu-
dies done with biologics vs chemical drug candidates. The last part of
the lecture highlighted the evaluation of potential immunotoxicity of
different types of drug candidates. There is a specific ICH S8 guidance
addressing this topic (Anon, 2005b), which is focused on drugs that are
not intended to affect the immune system. However, the real challenge
in drug safety assessment is to evaluate the immunotoxicity potential of
drug candidates (both chemical and biologics) that modulate immune
function by design. While we have a “tool box” with multiple in vitro, ex
vivo and in vivo models to study the immune system and its responses to
a drug treatment, we need to better understand inherent risks of im-
munomodulatory therapeutics during early non-clinical stages of drug
development, particularly for novel drugs to treat immuno-oncology
and immuno-inflammatory diseases.
3.6. Emerging technologies and novel therapeutic modalities
Rapid technological advances have a big impact on pharmaceutical
drug development. Novel technology is being adapted to methods and
models used both as in vitro and in vivo systems. Particularly, avail-
ability of transgenic mice, novel imaging techniques and reagents
B.D. Guth, et al. Journal of Pharmacological and Toxicological Methods 98 (2019) 106579
6
enabling the testing of materials and tissues at the molecular and ge-
netic level all play increasing roles in methodologies applied in drug
safety evaluation. In addition, we are facing an increasing number of
modalities as potential medicines, which include highly engineered
biochemical molecules, vaccines, human cells and genetic elements,
viral components, and hybrids of the above. Emergence of such un-
conventional therapeutic modalities brings many challenges into
pharmaceutical drug development, including approaches to safety as-
sessment. Dr. Herzyk presented a comprehensive survey of both these
challenges and the unprecedented therapeutic potential of these novel
approaches.
3.7. Carcinogenicity case study (James Smith, Boehringer-Ingelheim,
Ridgefield, CT)
Mr. James Smith brought together many of the concepts presented
during the toxicology session in the final presentation of the session: a
case study of the investigation undertaken to de-risk a promising new
therapeutic after unforeseen identification of a carcinogenicity risk late
in clinical development.
Empagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor,
indicated to lower blood glucose in the treatment of type 2 diabetes,
had successfully passed Phase 1 studies when a histopathology finding
of increased renal tumor incidence in male mice in a 2-year carcino-
genicity study necessitated comprehensive mechanistic studies to de-
risk the compound and enable further clinical progression. This finding
was unexpected, as it was not directly attributable to suprapharma-
cology, was not observed in rats or dogs (Bogdanffy, Stachlewitz, van
Tongeren, et al., 2014; Knight, Yuan, Koegler, et al., 2018) and empa-
gliflozin was not shown to be genotoxic in standard assays.
Due to the type of finding, a definition of the mechanism of action
leading to the lesion was deemed more important than safety margins.
Establishment of a chain of pathological events resulting in tumor
formation was undertaken as well as the characterization of the human
relevance versus mouse specificity of each step. The key events, which
are all necessary but not individually sufficient, were: 1) a predisposing
cystogenic background in mice, 2) added SGLT2 pharmacology-related
renal stress, 3) non-pharmacology-related renal stress, 4) exhaustion of
stress handling reserves, and 4) conversion to constitutive cell growth.
Experimental investigations of the key events were done using in vivo
and in vitro studies. A 13-week investigative pathogenesis study in mice
identified gender differences in gene expression patterns, renal tubular
flow and non-neoplastic degenerative/regenerative renal histo-
pathology preceding neoplasia (Knight et al., 2018). In addition to su-
prapharmacology-related osmotic diuresis, these findings support a
non-genotoxic mode of action. The weight of evidence was increased by
the in vitro identification of a male mouse-predominant renal metabolite
that is not present in humans and which leads to the generation of a
highly reactive aldehyde (Taub, Ludwig-Schwellinger, Ishiguro, et al.,
2015). Further characterization of this metabolite confirmed that it was
cytotoxic but not genotoxic (Smith, Huang, Escobar, et al., 2017), while
empagliflozin was neither. Finally, renal in vivo gene expression data
confirmed the temporal profile of exhaustion or stress handling reserves
and the switch to constitutive cell growth (Knight et al., 2018). In
summary, empagliflozin induces pharmacology-related renal tubular
injury in the male mouse, exacerbating a genetic background predis-
posing cystogenic changes in males. Further renal stress is imposed by
nephrotoxic effects of a male mouse-predominant renal aldehydic me-
tabolite and oxidative stress facilitated by a predominantly oxidative
pathway of empagliflozin metabolism, which differs from the human
metabolic pathway. The weight of evidence on genotoxicity, gender
and mouse strain specificity, and the dose-response and temporal re-
lationships is consistent with a non-genotoxic mode-of-action having no
relevance to humans. This approach was used to enable successful
product launch.
4. Animal models for use in Safety Pharmacology & Toxicology
4.1. Modeling human disease for preclinical testing (Karen Svenson, The
Jackson Laboratory, USA)
Dr. Svenson presented a brief overview of The Jackson Laboratory
past and present and highlighted important considerations for building
and testing preclinical mouse models.
The Jackson Laboratory (JAX) is often perceived as only a dis-
tributor of research mice and its activities as a non-profit research in-
stitute are not as well known. The Laboratory was established in 1929
by scientists who believed in the genetic etiology of cancer. Now with
four campuses in the US, JAX comprises more than 50 Principal
Investigator‑lead programs in a broad range of disciplines and supports
graduate and postgraduate training programs. The Laboratory has been
a National Cancer Institute-designated Cancer Center since 1983.
Campuses are defined by their focus areas: Mammalian Genetics;
Genomic and Precision Medicine; In vivo, cancer and stem cell services;
and Production and Distribution of mice. In addition to a diversity of
inbred, hybrid and outbred strains with various features of numerous
human diseases, the laboratory offers highly specialized engineered
mouse models and serves as a repository for externally-derived models.
Of particular use in studying cancer, inflammatory and infectious dis-
ease and hematopoiesis are a series of humanized immunodeficient
models, popularly used for checkpoint inhibitor development and effi-
cacy testing of novel immunotherapies. A large library of patient-de-
rived xenograft (PDX) models are available to guide clinical ap-
proaches, and can be used by investigator-initiated projects or in JAX-
directed preclinical efficacy studies. Often working with Foundations to
import and distribute models with minimal licensing barriers, nu-
merous preclinical mouse models have been developed by enhancing
and refining existing disease models. Examples presented include im-
proved models for Spinal Muscular Atrophy (SMA) and Duschenne
Muscular Dystrophy. By partnering with Foundations, pharmaceutical
companies and biotechnology firms, JAX has established the Rare and
Orphan Disease Center to establish relevant models for use in pre-
clinical testing platforms including performing dosing studies.
Development of a robust preclinical mouse model can be ap-
proached in more than one way. A gene-centric approach starts with
single mouse or human target genes identified as having relevance to
human disease and presents them in well-defined genetic backgrounds.
Relevant genes can be ascertained using epidemiological data, data
from genome-wide association studies, or from basic research-driven
strategies revealing candidate genes involved in the etiology of disease
processes. Because mice and humans share many of the same diseases,
another approach is to survey existing inbred and engineered strains for
phenotypes that recapitulate key features of human diseases under
standard or manipulated environmental conditions, such as dietary
challenges. Models should follow an optimal timeline for disease pro-
gression that closely follows relative progression in humans; not too fast
and not too slow, so that interventions can be made and responses can
be tracked. Models must be phenotypically robust and highly penetrant.
Females and males must be used, unless the disease of interest is clearly
sex-specific. Using only one sex can lead to clinical trial and market
failures by not considering effects of treatments in both sexes. Different
mouse strains generally have very different genetic backgrounds, and
therefore it is imperative that a survey of at least a limited panel of
strains is performed to assess the disease of interest and how a genetic
manipulation behaves under varied backgrounds. Humans also have
varied genetic makeup and one size does not fit all. An example of the
diversity in side effects of chemotherapy drugs was presented to de-
monstrate that using just one mouse strain for drug testing would be
comparable to testing a drug only in identical twins. The utility of a
recently developed outbred strain was presented as a better system to
model variation in toxicity (Svenson et al., 2012). Finally, given the
important revelations emerging about the role of the gut microbiome in
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disease, Dr. Svenson urged the inclusion of microbial profiling in
evaluating preclinical models, both before and after drug treatment.
Mouse resources, investigator profiles and educational opportunities
can be further queried at http://www.jax.org.
4.2. Designing new genetically altered (GA) mouse lines for preclinical
research (Sara Wells, MRC Harwell Institute, UK)
For many years' geneticists have been altering the mouse genome,
initially in individual laboratories and over the last decade in larger
global consortia (www.mousephenotype.org) providing large catalo-
gues of genetically altered (GA) strains for the biomedical research
community. More recently the prolific use of genome editing tools has
accelerated the number of novel strains available. These truly are ex-
citing times for genetic research as accessibility to GA models (not just
of mice) becomes easier and their inclusion in more scientific programs
accelerates. The speed and rapid expansion in the use of genetic en-
gineering techniques also comes with the responsibility of rigorous
quality control at all levels from the wild type strains used for mod-
ifications to stringent analysis of the structure of novel alleles generated
and well-designed, controlled characterizations of new strains. CRISPR/
Cas 9 and other technologies are opening up a whole new range of
possibilities in terms of altering the genome and refining animal
models. This technology significantly shortened the period of time (less
than 6months) taken to generate mutations in the mouse genome that
can faithfully recapitulate those in human genomic studies. However,
these molecular tools are still in development and a significant amount
of quality control is required to ensure that unintended alterations at
the targeted loci or elsewhere in the genome have not occurred as these
pose a significant risk to the integrity of the experiment (Mianné et al.,
2017). Lastly, as our ability to hop and chop around the genome in-
creases, this must come with a concurrent increase in the sophistication
in the technologies we are using to analyze the GA strains and a dee-
pening of the ethical discussions ensuring that using a live animal is the
only option. Automation and non-subjective phenotyping will play a
pivotal role in the robustness and reproducibility of data delivered in
the future (Bains et al., 2016). We are in extraordinary times of huge
advancements in genetic science providing the opportunity to close
both the molecular and physiological gap between model organisms
and humans. Rigorous control of genetic integrity and experimental
design will be essential if this prospect is to be realized.
4.3. The INFRAFRONTIER Research Infrastructure – resources and services
to advance the understanding of human health and disease using
mammalian models (Asrar Ali Khan, INFRAFRONTIER GmbH, Germany)
Dr. Ali Khan provided an overview of INFRAFRONTIER, the
European Research Infrastructure for the development, phenotyping,
archiving and distribution of model mammalian genomes. The INFR-
AFRONTIER Research Infrastructure provides access to first-class tools
and data for biomedical research, and thereby contributes to improving
the understanding of gene function in human health and disease using
mice (Raess et al., 2016). The INFRAFRONTIER network currently
consists of 29 partners that are engaged in several European Commu-
nity funded projects, such as INFRAFRONTIER2020, Research Infra-
structure for Phenotyping, Arching and Distribution of Mouse Diseases
Models (IPAD-MD) and CORBEL, and contributes to the International
Mouse Phenotyping Consortium (IMPC). The core services of INFRAF-
RONTIER comprises of model generation, specialized phenotyping
services, systemic phenotyping of mouse mutants in the participating
mouse clinics, as well as archiving and distribution of mouse mutant
lines by the European Mouse Mutant Archive (EMMA). INFRAFRONT-
IER also offers specialized services, such as the generation of germ-free
mice (axenic service) and training in state-of-the-art cryopreservation
and phenotyping technologies. Reduction and refinement to improve
animal welfare are among the major goals of INFRAFRONTIER's
technology development programme. To promote international co-
operation and facilitate access to the global biomedical research com-
munity, INFRAFRONTIER offers trans-national access calls for projects
and provides funding based on proposal merit (INFRAFRONTIER
Consortium, 2015). So far 25 open calls have funded 378 user projects
with several high impact publications. The EMMA branch of INFRAF-
RONTIER offers the worldwide scientific community a free archiving
service for its mutant mouse lines and access to a wide range of disease
models and other research tools. EMMA currently holds nearly 7000
mutant mouse strains, half of which have been produced from the In-
ternational Mouse Knockout Consortium (IKMC) resource. The EMMA
network is comprised of 16 partners from 13 countries that operate as
the primary mouse repository in Europe. The afore-mentioned IPAD-
MD project addresses global cooperation and coordination between the
pan-European INFRAFRONTIER Research Infrastructure and com-
plementary research infrastructures in America, Asia and Australia
contributing to the global effort of the IMPC. The IPAD-MD project also
reaches out to complementary infrastructures and user communities in
Africa.
4.4. The International Mouse Phenotyping Consortium (IMPC) -
Phenotyping mice for drug development (Tertius Hough, MRC Harwell
Institute, UK)
The International Mouse Phenotyping Consortium (IMPC) is cur-
rently composed of 19 research institutions and 5 national funders from
11 countries. The consortium is building a catalogue of mammalian
gene function by producing and phenotyping a knockout line for every
protein-coding gene in the mouse genome (Dickinson, Flenniken, Ji,
et al., 2017). This involves the creation of 20,000 knockout mouse
strains on an isogenic C57BL/6 N background and characterizing each
strain through a standardized phenotyping protocol. Embryonic, Adult
and Terminal phenotyping pipelines were designed to assess em-
bryonic, neuromuscular, sensory, cardiovascular, metabolic, hemato-
logical, and neurological parameters (Brown, Holmes, Mallon, et al.,
2018). The associated phenotyping protocols were established by spe-
cialist working groups are continually refined and are freely available
from The International Mouse Phenotyping Resource of Standardized
Screens (IMPReSS, see: www.mousephenotype.org/impress). Teams of
dedicated data wranglers perform rigorous quality control and statis-
tical analysis on the data submitted to a central database. Further
analysis of these data includes disease / phenotype associations and
visualizations. All data are freely available via the IMPC portal (see:
www.mousephenotype.org). To date, the IMPC has generated and
characterized over 5200 mutant lines. One-third of the lines have been
found to be non-viable and over 300 new mouse models of human
disease have been identified so far (Meehan, Conte, West, et al., 2017)).
The mouse strains that have been generated are deposited in the KOMP
repository and the European Mutant Mouse Archive (EMMA). The in-
tegration of this valuable resource of phenotyping data with data from
the human genome is a powerful approach for the interpretation of
human genetic variation and its relationship to disease. In this way, the
IMPC is aiding in the identification of candidate genes for studying
human disease conditions and delivering information about the un-
derlying mechanisms (Rozman, Rathkolb, Oestereicher, et al., 2018)).
Access to the KO mouse strains and the freely available phenotyping
data produced by the IMPC consortium also represents a valuable re-
source for drug discovery and target validation.
5. Drug safety and the preclinical drug development platform
(PCDDP)
The PCDDP is a state-of-the-art facility situated on the
Potchefstroom campus of the North-West University in South Africa and
was established in 2011. This platform is meant to function as a na-
tional preclinical testing platform to conduct qualitative and
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quantitative preclinical studies for companies and research institutes in
Africa ultimately enabling South Africa to play a significant role in the
production of drugs and phyto-medicines. The scientists at the PCDDP
conduct safety pharmacology, pharmacokinetic and selected toxicology
studies for new compounds and/or formulations. The facility also de-
velops, establishes and maintains preclinical animal models related to
the treatment of many disorders including infectious disease, neuro-
biology and other chronic disease states. The PCDDP includes a state of
the art rodent vivarium that can breed rats and mice for use in studies
and permits the training of laboratory scientists to conduct of a wide
range of drug efficacy and safety studies. The vivarium is the first
Association for Assessment and Accreditation of Laboratory Animal
Care (AAALAC) International-accredited animal facility in sub-Saharan
Africa and is also qualified for the conduct of Good Laboratory Practice
(GLP) studies. The PCDDP has prioritized the establishment of in vitro
electrophysiological and in vivo SP models to conduct core battery (i.e.,
CNS, CV and respiratory) evaluations of NCEs in development by aca-
demics and pharmaceutical/biotechnology companies in South Africa.
Thus, this meeting drew preclinical drug development experts from
across the globe to South Africa to assist in enhancing the capability of
South Africa to participate in cutting-edge research and drug develop-
ment.
6. Abstracts overview
There were 18 posters presented at the meeting consisting of topics
ranging from selective targeting of cancer cells by using novel drug
delivery systems to the use of cytokines as indicators for drug safety.
These were presented primarily by students from across Africa. These
abstracts can be found elsewhere in this edition of the Journal of
Pharmacological & Toxicological Methods.
7. Conclusions
The first Drug Safety Africa Meeting in Potchefstroom, SA offered
the attendees a wide range of topics covering safety pharmacology and
toxicology study designs, models and issues that may be encountered.
Both sessions were marked with many highlights since both provoked
important questions and exciting discussions by meeting participants.
Overall, attendees (student, faculty and industry scientists) generally
felt this to be a highly successful meeting with the establishment of
many new scientific relationships. The establishment of a network of
scientists in Southern Africa with an interest in drug safety and with
connections to international scientists with similar interests is a cor-
nerstone for advancing drug safety in Africa. Given the success of this
meeting, plans for a subsequent meeting are already ongoing.
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